SeeByte and Kraken Robotics sign MOU
ST. JOHN’S, Newfoundland and Labrador, Sept. 03, 2024 (GLOBE NEWSWIRE) — SeeByte Ltd (SeeByte) and Kraken Robotics Inc. (Kraken) have […]
New Report: Average Annual Natural Catastrophe Losses for the Insurance Industry Reaches New High of $151 Billion
BOSTON, MA, Sept. 03, 2024 (GLOBE NEWSWIRE) — Verisk (Nasdaq: VRSK), a leading global data analytics and technology provider, is […]
Volt Lithium Provides Notice of Upcoming Annual General and Special Meeting
CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) — Volt Lithium Corp. (TSXV: VLT | OTCQB: VLTLF I FSE: I2D) (“Volt” […]
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER […]
Falcon Oil & Gas Ltd. – Falcon Announces Planned Share Consolidation and Name Change to pursue U.S. Listing
FALCON OIL & GAS LTD. (“Falcon” or the “Company”) Falcon Announces Planned Share Consolidation and Name Change to pursue U.S. […]
BHP Xplor Launches Search for Innovators in Critical Minerals Exploration
TORONTO, Sept. 03, 2024 (GLOBE NEWSWIRE) — BHP Xplor, the six-month accelerator program aimed at revolutionizing critical mineral exploration, has […]
Check Point Software Unveils New MSSP Portal for Partners: Vastly Simplifying Service Delivery and Ease of Doing Business
BANGKOK, Sept. 02, 2024 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading cyber security platform provider […]
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity […]
TSX News -
Velan Inc. Signs Main Services Agreement With GEH SMR Technologies Canada Ltd.
MONTREAL, Sept. 02, 2024 (GLOBE NEWSWIRE) — Velan Inc. (TSX: VLN) (“Velan” or the “Company”), a world-leading manufacturer of industrial […]
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic […]
